Avaí Bio, Inc. (AVAI)

OTCMKTS · Delayed Price · Currency is USD

0.0962

+0.0067 (7.46%)

Nov 6, 2026, 3:47 PM EST

Market Cap	14.81M -72.4%
Revenue (ttm)	n/a
Net Income	-1.81M
EPS	-0.01
Shares Out	153.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,700
Open	0.0962
Previous Close	0.0895
Day's Range	0.0881 - 0.1028
52-Week Range	0.0830 - 0.8000
Beta	0.31
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Avaí Bio

Avaí Bio, Inc. acquires, creates, and develops artificial intelligence (AI) technologies. It also offers information technology (IT) consulting services. The company provides full-stack software development, database management, data integration, project management and cloud services resources. It also offers Avant! AI, a platform that has shown impressive results related to the technology’s usage, access, and performance; and InstantFAME. The company was formerly known as Avant Technologies Inc. and changed its name to Avaí Bio, Inc. in Februa... [Read more]

Industry Software - Application

Sector Technology

Founded 2017

Country United States

Stock Exchange OTCMKTS

Ticker Symbol AVAI

Full Company Profile

Financial Performance

Financial Statements

News

Avaí Bio and Austrianova Announce Publication in Frontiers in Aging Journal Highlighting Novel Cell Encapsulation-Based Approach to Sustained Klotho Delivery

LAS VEGAS, NV, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotech developing transformative cell-based therapies for diabetes, age-related di...

9 days ago - GlobeNewsWire

Avaí Bio and Austrianova Hold First Joint Steering Committee Meeting with Ospedale San Raffaele for Diabetes Cell Therapy Program

LAS VEGAS, NEVADA, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and its joint venture partner Austrianova, today announced the first joint steering committe...

4 weeks ago - GlobeNewsWire

Avaí Bio and Austrianova Successfully Encapsulate GMP-Quality Klotho-Producing Cells, Achieve Robust Klotho Secretion

LAS VEGAS, NEVADA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotech developing transformative cell-based therapies for diabetes, age-relat...

5 weeks ago - GlobeNewsWire

Avaí Bio and Austrianova Present Encapsulated Cell Approach to Sustained α-Klotho Delivery at 2026 Klotho Conference

Avaí Bio and Austrianova presented an encapsulated-cell approach to sustained α-Klotho delivery via Klothonova at the 2026 Klotho Conference in Miami.

6 weeks ago - GlobeNewsWire

Avaí Bio and Austrianova Complete Adventitious Agent Testing of Master Cell Bank, Establish Working Cell Bank for α-Klotho Anti-Aging Therapy

Avaí Bio and Austrianova complete viral and adventitious agent testing of the Master Cell Bank and establish a Working Cell Bank for α-Klotho therapy.

7 weeks ago - GlobeNewsWire

Avaí Bio and Austrianova Announce Research Collaboration with San Raffaele Hospital to Advance Encapsulated Cell Therapy for Diabetes

LAS VEGAS, NEVADA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and Austrianova, its joint venture partner in Insulinova, today announced that Insulinova ha...

2 months ago - GlobeNewsWire

Avaí Bio and Austrianova Reach Agreement for Insulin-Producing Cells with Internationally Acclaimed Partner to Advance Diabetes Therapy

LAS VEGAS, July 21, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-rela...

3 months ago - PRNewsWire

Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy

LAS VEGAS, May 20, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-relat...

5 months ago - PRNewsWire

Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference

LAS VEGAS, April 7, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-rela...

7 months ago - PRNewsWire

Avaí Bio and Austrianova Begin Production of Master Cell Bank for Klotho Anti-Aging Therapy Under GMP Standards

LAS VEGAS, March 3, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-rela...

8 months ago - PRNewsWire

Avant Technologies Completes Rebranding with Name Change to Avaí Bio and Launch of New Website

LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and...

8 months ago - PRNewsWire

Avant Technologies Evaluating Advanced Cells for Diabetes Therapy at 15th Annual EPITA Symposium

LAS VEGAS, Jan. 26, 2026 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes an...

9 months ago - PRNewsWire

Avant Technologies Highlights the Critical Role of Cell Encapsulation Technology in Revolutionizing Diabetes Treatment

LAS VEGAS , Dec. 16, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes a...

10 months ago - PRNewsWire

Avant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival

LAS VEGAS , Dec. 9, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes an...

11 months ago - PRNewsWire

THE CRITICAL LIST: 5 Stocks Anchoring the New Economy

Issued on behalf of Quantum Security Encryption Corp. VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- USANewsGroup .com Market Intelligence Brief – The market is in triage. Speculative ...

11 months ago - GlobeNewsWire

Avant Technologies and Austrianova Secure Exclusive License for Klotho Producing Cell Line to Advance Anti-Aging Therapies

LAS VEGAS--(BUSINESS WIRE)--Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology company focused on developing cellbased therapies for diabetes and age-related ...

11 months ago - Business Wire

Avant Technologies Signs Joint Venture to Advance Cell-Based Diabetes Treatment

LAS VEGAS--(BUSINESS WIRE)--Avant Technologies Inc. (OTCQB: AVAI) (“Avant” or the “Company”), a Nevada-based corporation, and SGAustria Pte. Ltd. (SGAustria), a Singapore-based biotechnology company, ...

1 year ago - Business Wire

Avant Technologies and Austrianova Launch Klothonova, Begin Developing Age Related Cellular Therapies Using 'Longevity Protein' Klotho

LAS VEGAS , Oct. 21, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company") and global biotechnology firm, Austrianova, today announced the official launch of their join...

1 year ago - PRNewsWire

Avant Technologies, Inc. Bolsters Strategic Vision with Targeted Biotech Partnerships for Innovative Cell-Based Therapies

LAS VEGAS , Sept. 25, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company"), today announced a pivotal evolution in its business direction, emphasizing strategic partne...